References
- Miller B A, Ries L AG, Hankey B F, Kosary C L, Edwards B K. Cancer Statistics Review, 1973 – 1989. NIH Publication, no. 92-2789, National Institutes of Health, Rockville, MD 1992
- Burstein H J, Winer E P. Reproductive issues. Diseases of the Breast2nd edn., J R Harris, M E Lippman, M Morrow, C K Osborne. Lippincot Williams and Wilkins, Philadelphia, PA 2000; 1051–1059
- Blumenfeld Z, Avivi I, Ritter M, Rowe J M. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 1999; 6: 229–239
- Ries L AG, Miller B A, Hankey B F. SEER Cancer Statistics Review, 1973 – 1991. National Institutes of Health, Rockville, MD 1994, NIH Publication, no. 94 – 2789. National Cancer Institute
- Epelbaum R. Non-Hodgkin's lymphoma: long-term survivors and adverse effects. Ann Oncol 2000; 11(Suppl 3)123–128
- Dumontent C, Bastion Y, Felman P, Ffrench M, Blanc M, Peaud P Y, et al. Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 1992; 3: 639–644
- Haddy T B, Adde M A, McCalla J, Domanski M J, Datiles M, III, Meehan S C, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 2070–2079
- Muller U, Stahel R A. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 399–402
- Bokemeyer C, Schmoll H J, Van Rhee J, Kuczy K M, Schuppert F, Poliwada H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68: 105–110
- National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
- Carr B R, Bradshaw K D. Disturbances of menstruation and other common gynecologic complaints in women. Harrison's Principles of Internal Medicine, 15th edn, E Braunwald, A S Fauci, D L Kasper, S L Hanser, D L Longo, J L Jameson. McGraw-Hill, New York, NY 2001; 295–297
- Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999; 33: 65–76
- Franchi-Rezgni P, Rousselot P, Espie M, Briere J, Marolleau J P, Gisselbrecht C, et al. Fertility in young women after chemotherapy with alkilating agents for Hodgkin and non-Hodgkin's lymphomas. Hematol J 2003; 4: 116–120
- Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadona G. Gonadal toxicity after combination chemotherapy of Hodgkin's disease. Comparative studies of MOPP vs. ABVD. Eur J Cancer Clin Oncol 1985; 21: 601–605
- Shpilberg O, Lerner-Geva L, Ben-Bassat I, De-Mendosa A, Rabinovici J. Long term female fertility status following treatment for Hodgkin's disease. Blood 1998; 92(Suppl 1)365
- Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Long term sequelae from adjuvant chemotherapy. Recent Res Cancer Res 1993; 127: 247–255
- Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28: 157–158
- Janssen N M, Genta M S. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch Intern Med 2000; 160: 610–619
- Stillman R J, Schinfeld J S, Schiff I, Gelber R D, Greenberger J, Larson M, et al. Ovarian failure in long term survivors of childhood malignancy. Am J Obstet Gynecol 1981; 139: 62–66
- Howell S J, Shalet M S. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002; 4: 443–452
- Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe J M. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002; 13(Suppl 1)38–47